123
Participants
Start Date
August 31, 2020
Primary Completion Date
October 20, 2024
Study Completion Date
December 31, 2025
APG-2575
APG-2575 orally once daily, every 28 days as a cycle.
Rituximab
Rituximab 375mg/m2 ivgtt on C1D8 and 500mg/m2 ivgtt on C2-6D1.
Ibrutinib
Ibrutinib 420mg orally once daily during C1D8-28 and following cycles.
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
Chongqing Cancer Hospital, Chongqing
RECRUITING
Nanfang Hospital of Southern Medical University, Guangzhou
RECRUITING
Guangxi Medical University Affiliated Tumor Hospital, Nanning
RECRUITING
The Affiliated Hospital of Guizhou Medical University, Guiyang
RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
RECRUITING
Henan Provincial Oncology Hospital, Zhenzhou
RECRUITING
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
The First Affiliated Hospital of Nanjing Medical University, Nanjing
RECRUITING
Zhongda Hospital Southeast University, Nanjing
RECRUITING
The First affiliated hospital of Soochow University, Suzhou
RECRUITING
The First affiliated hospital of Nanchang University, Nanchang
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Fudan University Zhongshan Hospital, Shanghai
RECRUITING
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
RECRUITING
The First Bethune Hospital of Jilin University, Hangzhou
RECRUITING
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY